Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a ...

Several of the USA’s biggest pharmacy benefit managers (PBMs) have generated billions of dollars in revenue by charging ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Verastem Oncology licenses VS-7375 rights from GenFleet Therapeutics, aiming to target KRAS-driven cancers. Early Phase I ...

German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi ...

Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million ...

Mabwell Bioscience plans a secondary listing in Hong Kong to bolster development and global expansion. The move targets Hong ...

US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS ...

Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...

Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit ...

German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...

Japanese drugmaker Eisai and US partner Biogen announced today that the US Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (US brand name ...